-
Uncategorized1 week agoSTAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where...
-
Uncategorized1 week ago
Low-Cost, Portable Biotech Tools Improve Access to Bioresearch and Diagnostics
A global research team headed by scientists at University of Toronto’s Leslie Dan Faculty of Pharmacy has demonstrated the effectiveness of a suite of low-cost, portable...
-
Uncategorized1 week ago
ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off
Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king...
-
Uncategorized1 week agoHow one state’s medical meal program lowered health care costs
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. It’s officially Ice Cream Every Day...
-
Uncategorized1 week agoGene test guides more personalised breast cancer treatment
Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London...
-
Uncategorized1 week ago
Lilly bets $3B+ to add China’s Haisco to growing list of partners in five-program pact
Eli Lilly and the Haisco Pharmaceutical Group have yet to disclose what specific indications they plan to prioritize.
-
Uncategorized1 week ago
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival
When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts...
-
Uncategorized1 week ago
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines
-
Uncategorized1 week ago
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe. Read More
-
Uncategorized1 week ago
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
